Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Kyowa Hakko Kirin Joins Certara’s Simcyp Consortium

PRINCETON, NJ – Sept. 13, 2017 – Certara today announced that Kyowa Hakko Kirin Co., Ltd. has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium.

More Info

Paper Shows How Viral Kinetic Modeling Increases Influenza Knowledge & Advances Drug Development

PRINCETON, NJ – Sept. 6, 2017 – Certara today announced that its comprehensive influenza viral kinetic modeling review has just been published in Current Pharmacology Reports. As the number of drug-resistant influenza strains grows, researchers are searching for better ways to develop safer, more effective anti-viral drugs. Viral kinetic modeling, in combination with PK/PD modeling, is proving to be a fruitful resource.

More Info

Certara Endows Professorship at the UF College of Pharmacy

PRINCETON, NJ – June 28, 2017 – Certara today announced that it has endowed a professorship at the University of Florida College of Pharmacy’s Center for Pharmacometrics and Systems Pharmacology. The professorship will strengthen the relationship between the college’s academic program and industry to drive innovation and enhance the application of leading-edge science to solve current challenges.

More Info

Certara Launches CODEx to Inform Comparative Effectiveness and Drug Development Decisions

PRINCETON, NJ – June 6, 2017 – Certara today launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug development teams to easily visualize, explore, analyze and communicate content from Certara’s Clinical Trial Outcomes Databases and assess a given compound’s probability of success against competitor drugs.

Solution: Clinical Trials Simulation, Model-based Meta-analysis, PBPK Modeling & Simulation
More Info